Clinical nasal decongestant activity with oral antihistamines

Clinical and Experimental Allergy Reviews

Volumn 2, Issue 3, 2002, Pages 101-106

  Howarth, Peter ^a  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

Allergic rhinitis; Antihistamines; Fexofenadine; Nasal congestion

Indexed keywords

ANTIHISTAMINIC AGENT; AZELASTINE; CETIRIZINE; CYTOKINE; DECONGESTIVE AGENT; DESLORATADINE; FEXOFENADINE; MIZOLASTINE;

ALLERGIC RHINITIS; ANTIINFLAMMATORY ACTIVITY; BLOOD VESSEL PERMEABILITY; HUMAN; INFLAMMATION; NOSE CONGESTION; PRIORITY JOURNAL; REVIEW;

EID: 13644256587     PISSN: 14729725     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1472-9725.2002.00046.x     Document Type: Review

References (33)

1. Gregory C, Cifaldi M, Turner LA. Targeted intervention programmes: creating a customised practice model to improve the treatment of allergic rhinitis in a managed care population. Am J Manag Care 1999; 5:485-91.
2. Wright AL, Holberg CJ, Martinez FD et al. Epidemiology of physician diagnosed allergic rhinitis in childhood. Paediatrics 1994; 94:895-901.
3. Strachan D, Sibbald B, Weiland S et al. Worldwide variations in prevalence of symptoms of allergic rhino-conjuctivitis in children: the international study of asthma and allergies in childhood (ISAAC). Paediatric Allergy Immunol 1997; 8:161-76.
4. Nash DB, Sullivan SD, Mackowiak J. Optimising quality of care and cost effectiveness in treating allergic rhinitis in a managed case setting. Am J Manag Care 2000; 6 (Suppl.):3-15.
5. Malone D, Lawson K, Smith D, Arrighi H, Battista C. A cost of illness study of allergic rhinitis in the United States. J Allergy Clin Immunol 1997; 99:22-7.
6. Gomez E, Corrado OJ, Baldwin DL, Swanston AR, Davies RJ. Direct in vivo evidence for mast cell degranulation during allergen-induced reactions in man. J Allergy Clin Immunol 1986; 78:637-45.
7. Howarth PH, Wilson S, Lau L, Rajakulasingam K. The nasal mast cell and rhinitis. Clin Exp Allergy 1991; 21 (Suppl. 21):3-8.
8. Bradding P, Feather IH, Wilson S et al. Direct in vivo evidence for mast cell degranulation during allergen-induced reactions in man. J Immunol 1993; 151:3853-65.
9. Bradding P, Mediwake R, Feather IH et al. TNF alpha is localized to nasal mucosal mast cells and is released in acute allergic rhinitis. Clin Exp Allergy 1995; 25:406-15.
10. Bentley AM, Jacobson MR, Cumberworth V et al. Immunohistology of the nasal mucosa in seasonal allergic rhinitis: increases in activated eosinophils and epithelial mast cells. J Allergy Clin Immunol 1992; 89:877-83.
11. Montefort S, Holgate ST, Howarth PH. Leucocyte-endothelial adhesion molecules and their role in bronchial asthma and allergic rhinitis. Eur Resp J 1993; 6:1044-54.
12. Bochner BS, Schleimer RP. The role of adhesion molecules in human eosinophil and basophil recruitment. J Allergy Clin Immunol 1994; 94:427-38.
13. Kawabori S, Okuda M, Unno T, Nakamura A. Dynamics of mast cell degranulation in human allergic nasal epithelium after provocation with allergen. Clin Allergy 1985; 15:509-15.
14. Mygind N, Secher C, Kirkegaard J. Role of histamine and antihistamines in the nose. Eur J Respir Dis Suppl 1983; 128 (1): 16-20.
15. Howarth PH, Holgate ST. Comparative trial of two non-sedative H1 antihistamines, terfenadine and astemizole, for hay fever. Thorax 1984; 39:668-72.
16. International Rhinitis Management Working Group. International Consensus Report on the diagnosis and management of rhinitis. Allergy 1994; 49 (Suppl. 19):1-34.
17. Van Cauwenberge P, Bachert C, Passalaqua G et al. Consensus statement on the treatment of allergic rhinitis. European Acad Allergol Clin Immunol Allergy 2000; 55:116-34.
18. Howarth PH, Salagean M, Dokic D. Allergic rhinitis: not purely a histamine-related disease. Allergy 2000; 55 (Suppl. 64):7-16.
19. Howarth PH. Mediators of nasal blockage in allergic rhinitis. Allergy 1997; 52 (Suppl. 40):12-8.
20. Bernstein DI, Schoenwetter WF, Nathan RA, Storms W, Ahlbrandt R, Mason J. Efficacy and safety of fexofenadine hydrochloride for treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 1997; 79:443-8.
21. Casale TB, Andrade C, Qu R. Safety and efficacy of once-daily fexofenadine HCl in the treatment of autumn seasonal allergic rhinitis. Allergy Asthma Proc 1999; 20:193-8.
22. Howarth P, Stern M, Roi L, Reynolds R, Bousquet J-P. Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal allergic rhinitis. J Allergy Clin Immunol 1999; 104:927-33.
23. Van Cauwenberge P, Juniper E. Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120 mg, loratadine 10 mg and placebo administered once daily for the treatment of seasonal allergic rhinitis. Clin Exp Allergy 2000; 30:891-9.
24. Kittner B, Austin M, McKenzie D. Pooled analysis of once-daily fexofenadine on nasal congestion and other SAR symptoms. Allergy 2001; 56 (Suppl. 68):78. (Abstract 228).
25. Church MK, Gradidge CF. Inhibition of histamine release from human lung in vitro by antihistamines and related drugs. Br J Pharmacol 1980; 69:663-7.
26. Hamasaki Y, Shafigeh M, Yamamoto S et al. Inhibition of leukotriene synthesis by azelastine. Ann Allergy Asthma Immunol 1996; 76:469-75.
27. 1 antagonist. Allergy Proc 1991; 12:187-91.
28. Naclerio RM, Proud D, Kagey-Sobotka A, Freidhoff L, Norman PS, Lichtenstein LM. The effect of cetirizine on early allergic response. Laryngoscope 1989; 99:596-9.
29. Herman D, Garay R, Le Gal M. A randomized double-blind placebo controlled study of azelastine nasal spray in children with perennial rhinitis. Int J Pediatr Otorhinolaryngol 1997; 39:1-8.
30. Wilson A, Dempsey OJ, Sims EJ, Coutie WJ, Paterson MC, Lipworth BJ. Evaluation of treatment response in patients with seasonal allergic rhinitis using domiciliary nasal peak inspiratory flow. Clin Exp Allergy 2000; 30:833-8.
31. De Paulis A, Dente V, Onorati A, de Crescenzo G, Di Gioia L, Marone G. Fexofenadine inhibits the release of mediators and IL-4 from human FC, RI+cells. Allergy 1999; 54 (Suppl.):144. (Abstract P278).
32. Amon S, Amon U, Gibbs BJ. Antiallergic activity of fexofenadine in vitro. Allergy Clin Immunol 2000; 105:S382 (Abstract 1116).
33. Abdelaziz MM, Devalia JL, Khair OA, Bayram H, Prior AJ, Davies RJ. Effect of fexofenadine on eosinophil-induced changes in epithelial permeability and cytokine release from nasal epithelial cells of patients with seasonal allergic rhinitis. J Allergy Clin Immunol 1998; 101:410-20.